Abstract
Current rhinometric and flow assessments measure nasal patency and are often poorly correlated with rhinitis symptoms. To evaluate magnetic resonance imaging (MRI) as a new method to measure inflammatory changes in nasal and sinus mucosa following nasal allergen challenge. A pilot study (n = 6) determined the optimal technical settings for MRI to measure inflammatory change which were then adopted for the main study. This study was a single blind, placebo-controlled, three-way crossover trial in 14 subjects with seasonal allergic rhinitis. Effects of cetirizine, cetirizine and pseudoephedrine (Cet+PE), or placebo on total nasal symptom scores (TNSS), peak nasal inspiratory flow (PNIF), nasal nitric oxide (nNO), acoustic rhinometry, and MRI end points following nasal intranasal allergen challenge were measured. There were significant changes in all parameters after allergen challenge (P < 0.01), except for nNO. MRI end points were less variable and more consistent than PNIF and acoustic rhinometry in detecting changes after allergen challenge. Total nasal airspace volume was the most sensitive and reproducible MRI measurement, with a mean reduction from -5.37 cm(3) (95%CI -7.35, -3.38; P < 0.001), which was maximal 60 min after allergen challenge. A change of one in TNSS corresponded to a change in MRI volume of -0.57 cm(3). There was an improvement in all parameters (except nNO) in subjects taking Cet+PE compared with placebo, however this did not achieve significance probably because of the small study size (overall analysis P > 0.07; comparison of active versus placebo P > 0.09). MRI provides novel insights into the anatomical inflammatory changes post allergen challenge and provides a new method for assessment of nasal patency and objective measurement of inflammatory responses.
Highlights
Nasal provocation has been used to investigate the pathophysiology of allergic and non-allergic rhinitis, and is thought to have potential value for the evaluation of mechanisms of inflammation in both upper and lower airways, because of the similarity of the inflammatory responses to allergen challenge [1]
We compared the effect of single doses of Cet (10 mg) alone or Cet (10 mg) and PE (120 mg) in combination versus placebo to evaluate magnetic resonance imaging (MRI) end points against symptom scores (TNSS, visual analog scale (VAS), and nasal symptom score for congestion Nasal symptom score for congestion (NSSC)), measurements of nasal patency [4, 9], acoustic rhinometry, peak nasal inspiratory flow (PNIF), acoustic rhinometry of nasal volume and minimum cross sectional area (ARMXCA) and nasal nitric oxide [10,11,12]
The mean change and changes from baseline for total nasal symptom scores (TNSS) was D6.55 (95%CI 4.16, 8.94; P < 0.001), PNIF was DÀ28.77 (95%CI À46.58, À10.96; P < 0.002), and VAS was D26.67 (95%CI 12.20, À4114; P < 0.001)
Summary
Nasal provocation has been used to investigate the pathophysiology of allergic and non-allergic rhinitis, and is thought to have potential value for the evaluation of mechanisms of inflammation in both upper and lower airways, because of the similarity of the inflammatory responses to allergen challenge [1]. The evaluation of therapies for allergic rhinitis have used symptom-based scores (total nasal symptom score; TNSS) or visual analog scale (VAS) methods, despite the subjective. H1-receptor antagonists (anti-histamines) are widely prescribed for the treatment of allergic rhinitis but have limited clinical efficacy. We compared the effect of single doses of Cet (10 mg) alone or Cet (10 mg) and PE (120 mg) in combination versus placebo to evaluate MRI end points against symptom scores (TNSS, VAS, and nasal symptom score for congestion NSSC), measurements of nasal patency [4, 9], acoustic rhinometry, peak nasal inspiratory flow (PNIF), acoustic rhinometry of nasal volume and minimum cross sectional area (ARMXCA) and nasal nitric oxide (nNO) [10,11,12]. The study was conducted in two parts, with an initial pilot phase to determine the relevant MRI parameters and a second study as a single-blind three-way cross over study
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.